Charles River Laboratories International, Inc. (NYSE:CRL) acquired KWS BioTest Ltd. for £18 million on January 11, 2018. The purchase price was approximately £15 million in cash along with a potential additional payment of up to £3 million based on future performance. Charles River Laboratories International, Inc. (NYSE:CRL) completed the acquisition of KWS BioTest Ltd. on January 11, 2018.